RecruitingPhase 2NCT07317206

Ayahuasca, Esketamine and PTSD

Effects of Single Dose of Ayahuasca or Esketamine on Posttraumatic Stress Disorder: a Randomized, Double-blinded Study

Sponsor

University of Sao Paulo

Enrollment

10 participants

Start Date

Dec 20, 2025

Study Type

INTERVENTIONAL

Conditions

Posttraumatic Stress Disorder (PTSD)

Summary

Double-blind, randomized trial comparing a single dose of oral ayahuasca or esketamine in patients with posttraumatic stress disorder.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether ayahuasca (a plant-based psychedelic used in traditional Amazonian ceremonies) and esketamine (a fast-acting antidepressant given as a nasal spray) can help reduce PTSD symptoms. **You may be eligible if...** - You have a diagnosis of post-traumatic stress disorder (PTSD) **You may NOT be eligible if...** - You have psychiatric conditions or other medical issues that would make participation unsafe (the study team will assess these individually) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.